Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All evaluated elements of the AI claim are supported by the provided ZEPBOUND label excerpts (5.1 and 4), including the nonclinical rat findings, human uncertainty (including MTC), contraindication language, patient counseling/symptoms, and uncertainty of routine calcitonin/ultrasound monitoring.
Category Scores
Accurate Statements
In rats, tirzepatide causes dose- and time-dependent thyroid C-cell tumors at clinically relevant exposures.
5.1 Risk of Thyroid C-Cell Tumors (dose-dependent and treatment-duration-dependent increase in thyroid C-cell tumors in a 2-year study at clinically relevant plasma exposures).
It is unknown whether ZEPBOUND causes thyroid C-cell tumors (including MTC) in humans.
5.1 (unknown whether ZEPBOUND causes thyroid C-cell tumors, including MTC; human relevance not determined).
ZEPBOUND is contraindicated in patients with personal/family history of MTC or MEN 2.
4 Contraindications (contraindicated in patients with a personal or family history of MTC or in patients with MEN 2; also referenced in 5.1).
Counsel patients and note symptoms.
5.1 (counsel regarding potential risk for MTC and inform patients of symptoms of thyroid tumors, e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).
Routine monitoring with calcitonin or ultrasound is of uncertain value.
5.1 (routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection; rationale provided in label).
Unsupported Statements
Contradictions
Important Omissions
The claim does not include the label’s additional details on routine monitoring rationale (e.g., low calcitonin test specificity, high background incidence of thyroid disease, and the further evaluation recommendation if calcitonin is elevated; also evaluation of thyroid nodules).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements accurately reflect labeled boxed-warning-adjacent safety content in 5.1 and contraindication language in 4, without adding unsupported or contradictory recommendations.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of label rationale and follow-up actions related to monitoring (e.g., further evaluation if calcitonin is elevated; evaluation of thyroid nodules).
Suggested Improvement
Include the label’s additional monitoring rationale and the label-directed evaluation steps when calcitonin is elevated or when nodules are found on exam/imaging, as described in 5.1.